Hologic pacifies US Federal Trade Commission and sells Mammotest to Siemens
This article was originally published in Clinica
Hologic is to sell all intellectual property relating to its Mammotest prone stereotactic bed breast biopsy systems (SBBS), which the company had recently acquired from Fischer Imaging, to diagnostic imaging rival Siemens Medical Solutions for $6.5m. The move followed a complaint filed last week by the US Federal Trade Commission (FTC), alleging that Hologic's acquisition of Fischer's prone SBBS business gave the former a monopoly in the US market for these devices.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.